Candrin Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 26 Year, 8 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 8.60 M
- Revenue Growth -18.77%
- Profit Growth 64.58%
- Ebitda 6.51%
- Net Worth -22.06%
- Total Assets -61.72%
About Candrin Pharma
Candrin Pharma Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 May 1998 and has a history of 26 years and eight months. Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.60 M.
Teegala Renuka and Teegala Reddy serve as directors at the Company.
Company Details
-
Location
Rangareddy, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230TG1998PTC029470
-
Company No.
029470
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 May 1998
-
Date of AGM
30 Sep 2017
-
Date of Balance Sheet
31 Mar 2017
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Candrin Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Teegala Reddy
|
Managing Director | 13-Aug-1999 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Teegala Renuka
|
Director | 25-May-1998 | Current |
Financial Performance of Candrin Pharma.
Candrin Pharma Private Limited, for the financial year ended 2015, experienced significant reduction in revenue, with a 18.77% decrease. The company also saw a substantial improvement in profitability, with a 64.58% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Candrin Pharma?
In 2017, Candrin Pharma had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹8.60 M
₹0
Charges Breakdown by Lending Institutions
- Uti Bank Limtied : 0.60 Cr
- State Bank Of Patiala : 0.26 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2007 | Uti Bank Limtied | ₹6.00 M | Open |
| 12 Mar 2007 | State Bank Of Patiala | ₹1.50 M | Open |
| 18 Dec 2000 | State Bank Of Patiala | ₹1.10 M | Open |
How Many Employees Work at Candrin Pharma?
Unlock and access historical data on people associated with Candrin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Candrin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Candrin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.